Medlive Technology Co., Ltd. (Medlive) filed its Monthly Return with the Hong Kong Stock Exchange for the period ended 30 April 2026, detailing a modest expansion in issued share capital driven by option exercises.

\n\nAuthorised capital unchanged\n• Authorised share capital remained at 50.00 billion ordinary shares with a par value of USD 0.00001 each, equivalent to USD 0.50 million. No changes were recorded during the month.

\n\nIssued share movement\n• Outstanding ordinary shares (excluding treasury shares) rose by 1.15 million to 740.11 million.\n• The increase represents approximately 0.16 % of the share base at the end of March 2026.\n• Medlive held no treasury shares before or after the reporting month.

\n\nDriver of share increase\n• All new shares stemmed from the exercise of 1.15 million options under the Pre-IPO Share Option Scheme adopted on 29 March 2021.\n• Exercise price: RMB 0.38 per share.\n• Cash proceeds received: RMB 0.44 million.\n• Post-exercise, 160,375 pre-IPO options remain outstanding.\n• The Post-IPO Share Option Scheme (approved 18 June 2021) was unchanged, with 69.02 million options still available for grant.

\n\nPublic float status\n• Management confirmed compliance with the minimum public float requirement of 24.98 % as stipulated by Hong Kong listing rules.

\n\nConclusion\nApril’s activity reflects routine equity dilution linked to employee incentive plans, with minimal impact on Medlive’s overall share capital structure and no effect on treasury share levels.